Investing in biotechnology equities offers a unique risk-reward profile characterized by the potential for exponential gains upon successful clinical trials or FDA drug approvals, balanced against high failure rates and regulatory volatility. What is your specific risk tolerance, target portfolio weight, and investment timeline for clinical-stage healthcare assets?